Namwiwat Medical PCL (BKK:NAM) Research & Development: ฿0 Mil (TTM As of Mar. 2026)


BKK:NAM Namwiwat Medical Corp PCL BKK:NAM
40 GF Score
Price ฿3.40
GF Value ฿6.04
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Namwiwat Medical PCL Research & Development?

Namwiwat Medical PCL BKK:NAM -1.73% 40 Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus rates BKK:NAM with a GF Score™ of 40/100 and a GF Value™ of ฿6.04 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Namwiwat Medical PCL's Research & Development for the three months ended in Mar. 2026 was ฿0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ฿0 Mil.

Namwiwat Medical PCL  (BKK:NAM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Namwiwat Medical PCL Research & Development Related Terms

Namwiwat Medical PCL Research & Development Historical Data

* Premium members only.

The historical data trend for Namwiwat Medical PCL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Namwiwat Medical PCL Research & Development Chart

Namwiwat Medical PCL Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Namwiwat Medical PCL Quarterly Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BKK:NAM
40GF Score
Namwiwat Medical Corp PCL BKK:NAM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Namwiwat Medical PCL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ฿0 Mil mean?
Namwiwat Medical PCL (BKK:NAM) has a Research & Development of ฿0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Namwiwat Medical PCL and its competitors.
Is Namwiwat Medical PCL's Research & Development too high?
Namwiwat Medical PCL's current Research & Development is ฿0 Mil. Overall, Namwiwat Medical PCL has a GF Score™ of 40/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's Research & Development compare to ABT and SYK?
Namwiwat Medical PCL's Research & Development of ฿0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Namwiwat Medical PCL and its competitors. Namwiwat Medical PCL's current Research & Development is ฿0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.04, compared to a current price of ฿3.40 — trading 43.7% below its estimated fair value. The current Research & Development is ฿0 Mil. Namwiwat Medical PCL's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?

Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued. The current stock price of ฿3.40 is trading 43.7% below its estimated GF Value™ of ฿6.04. GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.

Key valuation signals for BKK:NAM:

  • Research & Development: ฿0 Mil
  • GF Value™: ฿6.04 vs. price of ฿3.40 (43.7% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Namwiwat Medical PCL Business Description

Address 999/3-5 Moo 9 Prachauthit - Ku Sang Road, Nai Khlong Bang Pla Kot, Phra Samut Chedi, Samut Prakan, THA, 10290
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
40GF Score

Get the complete analysis for BKK:NAM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿3.40
Price
฿6.04
GF Value